Skip to main content

Advertisement

Table 2 Significance of PFTs in Chronic Lung involvement due to CTDs

From: Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases

Disease Items Correlation
RA
 ILD Decline of FVC ≥ 10% from 68.7 or any time from baseline Decline of DLCO% ≥ 10% from 48.1 or any time from baseline Mortality
DLCO% ≤ 54 FVC decline ≥10% DLCO decline ≥15% Progression
SSDs
 ILD Decline of FVC ≥10% or comprised between 5 and 10% with a decline of DLCO≥15% Progression
DLCO < 80 Clinical and NVC DA
 PAH DLCO ≤55 diagnosis
FVC/DLCO> 1.6 diagnosis
IIMs
 ILD FVC ≤ 60 prognosis
TLC Disease extent in FU
SjS
 OLD Reduction of VC, FEV1, FEV1/VC, DLCO Diagnosis and prognosis
 ILD DLCO, TLC Correlation with disease extent
SLE
 PAH HRR < 16 prognosis
  1. DA Disease Activity, DLCO diffusing capacity for carbon monoxide, FEV1 Forced Expiratory Volume in 1 s, FVC forced vital Capacity, HRR heart Rate Recovery, IIMs Idiopathic Inflammatory Myopathies, ILD Interstitial Lung Disease, NVC Nailfold Videocapillaroscopy, PAH Pulmonary Artery Hypertension, PFT Pulmonary Function Test, RA Rheumatoid Arthritis, SjS Sjögren Syndrome, SLE Systemic Lupus Erythematosus, SSDs Scleroderma Spectrum Disorders, TLC Total Lung Capacity, VC Vital Capacity